CD10 expression in the female genital tract: does it have useful diagnostic applications?

Esther Oliva, Oliva E
Advances in anatomic pathology · 2004 · doi:10.1097/01.pap.0000138140.81139.46 · PMID:15505532
review OA: closed public-domain-us
Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

This review examines CD10's diagnostic utility in the female genital tract, highlighting its limited value in mesenchymal tumors but potential use in endometriosis, distinguishing metastatic renal cell carcinoma from ovarian clear cell carcinoma, and identifying mesonephric hyperplasia.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-09 · read from full text ⓘ

This review evaluates the diagnostic utility of CD10 expression in female genital tract tumors, noting that its broad positivity across various neoplasms limits its specificity. While initially considered helpful for distinguishing endometrial stromal tumors from mimics, recent evidence indicates CD10 is expressed in a wide range of conditions, making it potentially misleading as a standalone marker. The paper highlights specific contexts where CD10 remains valuable, such as differentiating mesonephric from non-mesonephric carcinomas and identifying metastatic renal cell carcinoma in the ovary. Relevance to endometriosis: listed as one indication for CD10 use, specifically for establishing the diagnosis of endometriosis in most sites except the cervix.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

In the female genital tract, CD10 was initially found to be expressed in endometrial stromal tumors of the uterus as well as in mesonephric remnants and related lesions and was thought to be helpful in distinguishing these tumors from their mimics. However, new studies have shown CD10 to be expressed in a wide range of tumors of the female genital tract, making this antibody of limited diagnostic value. This review discusses diagnostic applications of CD10 in the female genital tract, with emphasis on CD10 use in mesenchymal tumors of the uterus and in the differential diagnosis of mesonephric versus non-mesonephric carcinomas, where CD10 positivity alone may be misleading in the final classification of a tumor. CD10 may be useful in establishing the diagnosis of endometriosis (with the exception of the cervix), distinguishing metastatic renal clear cell carcinoma from a primary ovarian clear cell carcinoma, and distinguishing mesonephric hyperplasia from other benign glandular proliferations of the cervix.
Full text 1,136 characters · extracted from oa-doi-fallback · click to expand
CD10 Expression in the Female Genital Tract Does It Have Useful Diagnostic Applications? - Esther Oliva Abstract: In the female genital tract, CD10 was initially found to be expressed in endometrial stromal tumors of the uterus as well as in mesonephric remnants and related lesions and was thought to be helpful in distinguishing these tumors from their mimics. However, new studies have shown CD10 to be expressed in a wide range of tumors of the female genital tract, making this antibody of limited diagnostic value. This review discusses diagnostic applications of CD10 in the female genital tract, with emphasis on CD10 use in mesenchymal tumors of the uterus and in the differential diagnosis of mesonephric versus non-mesonephric carcinomas, where CD10 positivity alone may be misleading in the final classification of a tumor. CD10 may be useful in establishing the diagnosis of endometriosis (with the exception of the cervix), distinguishing metastatic renal clear cell carcinoma from a primary ovarian clear cell carcinoma, and distinguishing mesonephric hyperplasia from other benign glandular proliferations of the cervix.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Genital Neoplasms, Female Genital Neoplasms, Female Neprilysin Biomarkers, Tumor Biomarkers, Tumor Diagnosis, Differential Female Genital Neoplasms, Female Genital Neoplasms, Female Humans Neprilysin

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-09-20T06:14:45.862862+00:00
pubmed
last seen: 2026-05-13T22:12:26.305326+00:00
unpaywall
last seen: 2026-09-20T06:29:17.529187+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine